Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Transmedics Group Inc’s stock clocked out at $121.31, down -2.73% from its previous closing price of $124.71. In other words, the price has decreased by -$2.73 from its previous closing price. On the day, 0.64 million shares were traded.
Ratios:
To gain a deeper understanding of TMDX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.32 and its Current Ratio is at 9.10. In the meantime, Its Debt-to-Equity ratio is 1.95 whereas as Long-Term Debt/Eq ratio is at 1.94.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on December 17, 2024, Downgraded its rating to Neutral and sets its target price to $75 from $116 previously.
Oppenheimer reiterated its Outperform rating for the stock on October 29, 2024, while the target price for the stock was revised from $200 to $125.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 09 ’25 when Basile Edward M sold 6,000 shares for $115.63 per share. The transaction valued at 693,780 led to the insider holds 732 shares of the business.
EDWARD BASILE bought 6,000 shares of TMDX for $693,780 on May 09 ’25. On Mar 03 ’25, another insider, Khayal Tamer I, who serves as the Chief Commercial Officer of the company, sold 2,407 shares for $76.43 each. As a result, the insider received 183,967 and left with 36,042 shares of the company.
Valuation Measures:
As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 89.16, and their Forward P/E ratio for the next fiscal year is 48.68. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.96. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.41 while its Price-to-Book (P/B) ratio in mrq is 15.41.
Stock Price History:
Over the past 52 weeks, TMDX has reached a high of $177.37, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is 39.90%, while the 200-Day Moving Average is calculated to be 22.56%.
Shares Statistics:
A total of 33.83M shares are outstanding, with a floating share count of 32.59M. Insiders hold about 3.67% of the company’s shares, while institutions hold 117.14% stake in the company.
Earnings Estimates
The current market rating for Transmedics Group Inc (TMDX) reflects the collective analysis of 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.3, with high estimates of $0.36 and low estimates of $0.26.
Analysts are recommending an EPS of between $1.93 and $1.7 for the fiscal current year, implying an average EPS of $1.79. EPS for the following year is $2.48, with 6.0 analysts recommending between $2.75 and $2.12.
Revenue Estimates
In the current quarter, 8 analysts expect revenue to total $146.64M. It ranges from a high estimate of $150.01M to a low estimate of $144M. As of the current estimate, Transmedics Group Inc’s year-ago sales were $114.31MFor the next quarter, 8 analysts are estimating revenue of $140.82M. There is a high estimate of $145.3M for the next quarter, whereas the lowest estimate is $138.09M.
A total of 10 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $585.4M, while the lowest revenue estimate was $576.27M, resulting in an average revenue estimate of $579.82M. In the same quarter a year ago, actual revenue was $441.54MBased on 9 analysts’ estimates, the company’s revenue will be $692.39M in the next fiscal year. The high estimate is $721.6M and the low estimate is $651.75M.
